CLINICAL TRIAL: ETANERCEPT IN DERMATOMYOSITIS

临床试验：依那西普治疗皮肌炎

• 批准号: 7951201
• 负责人: Richard J. Barohn
• 金额: $ 1.82万
• 依托单位: UNIVERSITY OF KANSAS MEDICAL CENTER
• 依托单位国家: 美国
• 财政年份: 2009
• 资助国家: 美国
• 起止时间: 2009-04-01 至 2010-03-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7951201
• 关键词: Affect; Clinical Research; Clinical Trials; Computer Retrieval of Information on Scientific Projects Database; Dermatomyositis; Etanercept; Funding; Grant; Institution; Muscle; Patients; Pharmaceutical Preparations; Prednisone; Research; Research Personnel; Resources; Safety; Source; United States National Institutes of Health

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The purpose of this study is to determine the safety and tolerability of a medication known as etanercept in patients with DM. Also to see how etanercept and prednisone affect the strength and function of your muscles.

这个子项目是许多研究子项目中的一个 由NIH/NCRR资助的中心赠款提供的资源。子项目和 研究者（PI）可能从另一个NIH来源获得了主要资金， 因此可以在其他CRISP条目中表示。所列机构为 研究中心，而研究中心不一定是研究者所在的机构。 本研究的目的是确定一种名为依那西普的药物在糖尿病患者中的安全性和耐受性。 同时观察依那西普和强的松对肌肉力量和功能的影响。